Wegovy Semaglutide Injection Pen for Weight Loss

Wegovy 7.2 mg is the highest available dose of semaglutide, approved for use in the UK. It has been developed for patients with obesity who need a stronger level of appetite control and enhanced weight loss results after reaching their maintenance dose.

Wegovy works by mimicking the GLP-1 hormone, helping to reduce appetite, calm food cravings, and slow digestion so you feel fuller for longer. When combined with a healthy diet and increased physical activity, Wegovy 7.2 mg has been shown in clinical trials to deliver significantly greater average weight loss compared to lower doses.

Clinical Results

In clinical trials, patients using Wegovy 7.2 mg achieved:

• Average weight loss of up to 20.7% of body weight
• Around 1 in 3 patients losing 25% or more of their starting weight
• A consistent safety profile similar to existing Wegovy doses when used as prescribed

Who Is Wegovy 7.2 mg Suitable For?

Wegovy 7.2 mg is indicated for adults living with obesity. It is prescribed as an optional further step after a minimum of 4 weeks on the 2.4 mg once-weekly maintenance dose, for patients who would benefit from additional weight loss support.

How Wegovy 7.2 mg Is Taken

Wegovy 7.2 mg is taken once weekly using the dedicated 7.2 mg single dose pre-filled pen. This is a single-use device containing one pre-set 7.2 mg dose, with a built-in hidden needle — no needle changes are required. Simply remove the cap, press firmly against the skin, and hold until the yellow indicator bar stops moving (approximately 5–10 seconds). Each pack contains 4 pens, providing one month's supply.

Storing Wegovy 7.2 mg

The 7.2 mg single dose pre-filled pen should be stored in a refrigerator (2°C to 8°C). It may be kept unrefrigerated for up to 28 days at a temperature not above 30°C. Do not freeze. Discard if frozen or if left out of the refrigerator for more than 28 days.

How Are Wegovy and Mounjaro Different?

Mounjaro (tirzepatide) and Wegovy (semaglutide) are both injectable treatments used to support weight management, but they work in slightly different ways and may suit different patients. Wegovy is a GLP-1 receptor agonist, while Mounjaro targets both GLP-1 and GIP receptors, which may offer added benefits for some individuals. Both medications are taken once weekly and can be highly effective when combined with lifestyle changes. Choosing between them depends on factors such as treatment goals, side effect profile, availability, and individual response, which is why professional guidance is essential.

Some patients may need to switch between Wegovy and Mounjaro, either because of supply challenges or personal preference. While there are no clinical trials that directly study switching from one to the other, the process can be managed safely with guidance from a healthcare professional.

A short break between treatments is usually recommended. Most patients benefit from a washout period of around 7–14 days before starting the new medication. This helps reduce the chance of overlapping side effects and gives the body time to adjust.

Since the right approach depends on factors such as your medical history, current dosage, and treatment goals, our clinical team carefully reviews each case to make sure the transition is smooth and that you begin on the correct dose.

The table below outlines a guide for patients moving from Mounjaro to Wegovy.

Wegovy is consistently priced lower than Mounjaro across all equivalent dosing levels, making it the more cost-effective option for most patients. While some individuals on lower doses of Mounjaro may still find the treatment manageable, those on higher doses often benefit from switching to Wegovy to help reduce costs while maintaining treatment effectiveness.

Precautions For Use Of Wegovy

Always consult with your healthcare provider before starting Wegovy to determine if it is the appropriate option for you and to discuss any potential risks or interactions with other medications.

Most individuals taking Wegovy experience mild side effects. The most common side effects include nausea, diarrhoea, vomiting, constipation, abdominal pain, headache, fatigue, upset stomach, dizziness, bloating, belching, gas, stomach flu, heartburn, and a runny nose or sore throat. Data from the STEPUP trials showed an increased incidence of dysaesthesia with the 7.2mg dose which largely precluded without need for treatment.

Wegovy may also cause serious side effects, including:

• Pancreatitis (inflammation of the pancreas): If you experience severe, persistent abdominal pain, with or without vomiting, contact your healthcare provider immediately. The pain may radiate from the abdomen to the back.

• Gallbladder problems: Wegovy may lead to gallbladder issues, including gallstones, some of which may require surgery. Contact your healthcare provider if you develop symptoms such as upper abdominal pain, fever, jaundice (yellowing of the skin or eyes), or clay-coloured stools.

• Hypoglycaemia (low blood sugar): Individuals with type 2 diabetes, especially those taking medications such as sulfonylureas or insulin, may experience an increased risk of low blood sugar. This is both a common and potentially serious side effect. Talk to your healthcare provider about recognising and managing low blood sugar. Symptoms may include dizziness, blurred vision, anxiety, irritability, sweating, slurred speech, hunger, confusion, drowsiness, shakiness, weakness, headache, fast heartbeat, or feeling jittery. Be sure to check your blood sugar before and during treatment with Wegovy.

• Kidney problems: In individuals with existing kidney issues, diarrhoea, nausea, and vomiting can lead to dehydration, worsening kidney function. It is important to stay hydrated to minimise this risk.

• Serious allergic reactions: Discontinue use of Wegovy and seek immediate medical attention if you experience symptoms of a serious allergic reaction, such as swelling of the face, lips, tongue, or throat, difficulty breathing or swallowing, severe rash or itching, fainting, dizziness, or rapid heartbeat.

• Vision changes in individuals with type 2 diabetes: Notify your healthcare provider if you experience any changes in vision while taking Wegovy.

• Increased heart rate: Wegovy can cause an increased heart rate at rest. If you experience a racing or pounding heart lasting several minutes, inform your healthcare provider.

• Mental health concerns (depression or thoughts of suicide): Pay close attention to any new or worsening mental health symptoms, such as changes in mood, behaviours, thoughts, or feelings. Contact your healthcare provider immediately if you experience any concerning changes.

Do not use Wegovy if you:

• Have or have had a family history of medullary thyroid carcinoma (MTC), a type of thyroid cancer, or if you have a condition known as Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

• Have had a serious allergic reaction to Semaglutide or any ingredient in Wegovy.

Before using Wegovy, inform your healthcare provider if you have any of the following conditions:

• A history of pancreatic or kidney problems.

• Type 2 diabetes with a history of diabetic retinopathy.

• A history of depression, suicidal thoughts, or mental health issues.

• Are pregnant or planning to become pregnant. Wegovy may harm an unborn baby, and you should stop using it at least 2 months before trying to conceive.

• Are you breastfeeding or plan to breastfeed? As it is unknown whether Wegovy passes into breast milk.

Always consult your healthcare provider for the most personalised and accurate advice.

Order Journey — Step by Step

Note: Next Day Delivery is counted from the time your prescription is approved by our prescriber, not from when you place your order.

At iQ Doctor, we take great care to ensure your Wegovy® pen arrives safely and in accordance with the latest manufacturer and MHRA guidance.

Read our latest update here.

What Should I Do First When The Wegovy Pen Arrives?

For best results, we recommend storing your pen in the fridge at 2°C–8°C until you are ready to use it.

To keep your medication in the best condition:

• Store it in its original carton to protect it from light.
• Do not freeze the pen. If it has been frozen, it should not be used.
• Keep it away from direct heat sources and sunlight.

What If The Pen Feels At Room Temperature When It Arrives?

There is no need to be concerned if your Wegovy pen arrives at room temperature.

Under updated MHRA-approved guidance, Wegovy can be transported at temperatures of up to 30°C for up to 48 hours during delivery without affecting the quality of the medication.

How Long Can I Keep Using It For?

• It can be stored at temperatures below 30°C for up to 6 weeks.
• A standard Wegovy pen contains four weekly doses, meaning your treatment course will typically be completed well within this timeframe.
• Store the pen away from direct sunlight and excessive heat.
• Always replace the pen cap after use.
• Never store the pen with a needle attached.

Questions About Your Delivery?

If you have any concerns about how your medication was delivered or stored, our clinical team is here to help. Please contact us before using your medication if you are unsure.